Bupropion for the Prevention of Postpartum Smoking Relapse
Status:
Recruiting
Trial end date:
2024-08-31
Target enrollment:
Participant gender:
Summary
This two-arm, double-blind, placebo-controlled randomized clinical trial will enroll pregnant
women who quit smoking after learning they were pregnant and are motivated to stay abstinent
postpartum. Participants will be randomized to receive extended-release bupropion (active
300mg or placebo once daily beginning 4 to 10 days postpartum to 12 weeks
post-randomization). All participants will complete the same data collection procedures
(e.g., biological sample collection for hormone and cotinine analysis and completion of
validated questionnaires) at baseline (gestational week 36), weekly from 4 to 10 days
postpartum through 12 weeks post-randomization and at weeks 12, 24, 36 and 52
post-randomization.
Phase:
Phase 4
Details
Lead Sponsor:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute